Tango Therapeutics Corporate Overview 2023 | Precision Oncology

Tango Therapeutics presents its corporate overview and pipeline strategy focused on precision oncology, emphasizing synthetic lethal approaches targeting tumor suppressor loss. The company highlights its lead PRMT5 inhibitor program (TNG908) for MTAP-null cancers and describes its discovery platform for developing next-generation cancer therapeutics with cash runway extending into 2025.